- Home
- CSTL vs ASPI Comparison
CSTL vs ASPI Comparison
Compare CSTL & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- ASPI
- Stock Information
- Founded
- CSTL 2007
- ASPI 2021
- Country
- CSTL United States
- ASPI United States
- Employees
- CSTL N/A
- ASPI N/A
- Industry
- CSTL Medical Specialities
- ASPI Major Chemicals
- Sector
- CSTL Health Care
- ASPI Industrials
- Exchange
- CSTL Nasdaq
- ASPI Nasdaq
- Market Cap
- CSTL 558.7M
- ASPI 470.6M
- IPO Year
- CSTL 2019
- ASPI 2022
- Fundamental
- Price
- CSTL $16.75
- ASPI $7.29
- Analyst Decision
- CSTL Strong Buy
- ASPI Strong Buy
- Analyst Count
- CSTL 6
- ASPI 2
- Target Price
- CSTL $38.33
- ASPI $4.50
- AVG Volume (30 Days)
- CSTL 548.5K
- ASPI 1.7M
- Earning Date
- CSTL 05-05-2025
- ASPI 05-23-2025
- Dividend Yield
- CSTL N/A
- ASPI N/A
- EPS Growth
- CSTL N/A
- ASPI N/A
- EPS
- CSTL N/A
- ASPI N/A
- Revenue
- CSTL $347,083,000.00
- ASPI $4,144,225.00
- Revenue This Year
- CSTL N/A
- ASPI $690.06
- Revenue Next Year
- CSTL $1.80
- ASPI $93.09
- P/E Ratio
- CSTL N/A
- ASPI N/A
- Revenue Growth
- CSTL 38.43
- ASPI 857.04
- 52 Week Low
- CSTL $15.70
- ASPI $1.86
- 52 Week High
- CSTL $35.84
- ASPI $9.33
- Technical
- Relative Strength Index (RSI)
- CSTL 34.74
- ASPI 69.87
- Support Level
- CSTL $15.84
- ASPI $6.30
- Resistance Level
- CSTL $17.49
- ASPI $6.94
- Average True Range (ATR)
- CSTL 0.90
- ASPI 0.47
- MACD
- CSTL -0.18
- ASPI 0.12
- Stochastic Oscillator
- CSTL 22.73
- ASPI 97.42
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.